top of page

ARVO 2025

Kuria has been accepted to present at ARVO 2025. The full poster will be available here following the live presentation. 

SCO-116, a novel small-molecule NRF2 activator, potently induces NQO1 in multiple monkey ocular tissues, including retina, after topical ocular administration

Keith W. Ward, Dave Flory, W. Brooks Gentry, Ralph Henry, Misty Stevens

Coming Soon Poster.png

ARVO 2024

Kuria presented three posters at ARVO 2024 in Seattle, WA. Click on the images to download. 

SCO-116 exhibits potent, selective activation of NRF2 suitable for use in treatment of ocular diseases

Ralph Henry, Dave Flory, W. Brooks Gentry, Yuko Katayama, Ryokichi Koyama, Shigemitsu Matsumoto, Yasuke Moritoh, Misty Stevens, Masanori Watanabe, Keith W. Ward

ARVO Poster 0192 Henry FINAL + QR Code 27 Feb 24.jpg

SCO-116, a novel small-molecule NRF2 activator, potently induces NQO1 in multiple rabbit ocular tissues

Misty Stevens, W. Brooks Gentry, Dave Flory, Ralph Henry, Brett Schneider, Keith W. Ward

ARVO Poster 4177 Stevens FINAL + QR Code 27 Feb 24.jpg

SCO-116 protects retinal pigment epithelium from oxidative insult in vitro and preserves visual function and retinal structure in sodium iodate-induced geographic atrophy in rats in vivo

Keith W. Ward, Rafal Farjo, Dave Flory, W. Brooks Gentry, Ralph Henry, Didier J. Nuno, Misty Stevens, Phillip Vanlandingham

ARVO Poster 1929 Ward FINAL + QR code 27 Feb 24.jpg

Copyright © 2024 Kuria Therapeutics, Inc.

bottom of page